Article
Antibiotic exposure and interpersonal variance mask the effect of ivacaftor on respiratory microbiota composition.
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society - 1 Jan 2018
Peleg Anton Y, Choo Jocelyn M, Langan Katherine M, Edgeworth Deirdre, Keating Dominic, Wilson John, Rogers Geraint B, Kotsimbos Tom
Abstract excerpt
BACKGROUND: G551D is a class III mutation of the cystic fibrosis transmembrane regulator (CFTR) that results in impaired chloride channel function in cystic fibrosis (CF). Ivacaftor, a CFTR-potentiating agent improves sweat chloride, weight, lung function, and pulmonary exacerbation rate in CF patients with G551D mutations, but its effect on the airway microbiome remains poorly characterised. METHODS: Twenty CF...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.